Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 2/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 10/20 | 0.42 |
| ▸ | ESR1 | P03372 | 6/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11151585 | 0.96 | CARM1 (0.49) | CARM1PRMT6NAAAASAH1ESR2 | |
| SCHEMBL18655446 | 0.93 | CARM1 (0.44) | CARM1PRMT6NAAAASAH1ESR2 | |
| SCHEMBL18588605 | 0.87 | ESR2 (0.58) | CARM1PRMT6ESR2ESR1CYP3A4 | |
| SCHEMBL22324977 | 0.81 | SLC18A3 (0.50) | — | |
| SCHEMBL8725437 | 0.81 | ALDH1A1 (0.47) | CARM1PRMT6ESR2ESR1CYP3A4 | |
| SCHEMBL8725107 | 0.81 | ESR2 (0.36) | CARM1PRMT6ESR2ESR1CYP3A4 | |
| SCHEMBL8732646 | 0.81 | ESR2 (0.36) | CARM1PRMT6ESR2ESR1CYP3A4 | |
| SCHEMBL8725432 | 0.81 | ALDH1A1 (0.47) | CARM1PRMT6ESR2ESR1CYP3A4 | |
| SCHEMBL8732537 | 0.81 | ESR2 (0.36) | CARM1PRMT6ESR2ESR1CYP3A4 | |
| SCHEMBL8732539 | 0.81 | ESR2 (0.36) | CARM1PRMT6ESR2ESR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081587-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-03-23 | — | — | US | disclosed |
| US-20170081587-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081587-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE INCLUDING THE SAME | C2CD5, C1S, CCR10 | CARM1 2688/4885PRMT6 3626/4885NAAA 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.